Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2016 1
2017 3
2018 1
2020 2
2021 1
2022 3
Text availability
Article attribute
Article type
Publication date

Search Results

10 results
Results by year
Filters applied: . Clear all
Page 1
Inactivation of Cancer Mutations Utilizing CRISPR/Cas9.
Gebler C, Lohoff T, Paszkowski-Rogacz M, Mircetic J, Chakraborty D, Camgoz A, Hamann MV, Theis M, Thiede C, Buchholz F. Gebler C, et al. Among authors: mircetic j. J Natl Cancer Inst. 2016 Aug 30;109(1):djw183. doi: 10.1093/jnci/djw183. Print 2017 Jan. J Natl Cancer Inst. 2016. PMID: 27576906 Free PMC article.
Using CRISPR-Cas9 to Dissect Cancer Mutations in Cell Lines.
Sayed S, Sürün D, Mircetic J, Sidorova OA, Buchholz F. Sayed S, et al. Among authors: mircetic j. Methods Mol Biol. 2022;2508:235-260. doi: 10.1007/978-1-0716-2376-3_18. Methods Mol Biol. 2022. PMID: 35737245
Common variants at 8q24 are associated with prostate cancer risk in Serbian population.
Branković AS, Brajušković GN, Mirčetić JD, Nikolić ZZ, Kalaba PB, Vukotić VD, Tomović SM, Cerović SJ, Radojičić ZA, Savić-Pavićević DL, Romac SP. Branković AS, et al. Among authors: mircetic jd. Pathol Oncol Res. 2013 Jul;19(3):559-69. doi: 10.1007/s12253-013-9617-1. Epub 2013 Mar 28. Pathol Oncol Res. 2013. PMID: 23532531 Free article.